GSK and London based Engitix Therapeutics announced today they will collaborate on first in class targets for liver fibrosis regression using Engitix's extracellular matrix (ECM) discovery platform

37 minutes ago
1 min read

GSK will pay Engitix approximately $59M up front and up to approximately $157M more in potential milestones. Engitix Co-Founder and CEO Giuseppe Mazza discusses the deal and the company's platform.

Recent Posts

See All

From the New York Stock Exchange, AstraZeneca CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more

Protuoso Biosciences exited stealth this past week with the goal of developing multifunctional MUXBODY biologics, fusion proteins that integrate diverse modalities into a single therapy

HEPHAISTOS Pharma is developing a TLR4 agonist meant to overcome immunosuppressive tumor environments. It has benefited from Paris Saclay Cancer Cluster's BOOST activator program

GSK and London based Engitix Therapeutics announced today they will collaborate on first in class targets for liver fibrosis regression using Engitix's extracellular matrix (ECM) discovery platform

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight